DE69618601T2 - Herstellung von einer immunantwort gegen prostat-spezifisches antigen (psa) - Google Patents

Herstellung von einer immunantwort gegen prostat-spezifisches antigen (psa)

Info

Publication number: DE69618601T2
Authority: DE; Germany
Prior art keywords: psa; host; prostate; cell; cells
Prior art date: 1995-07-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69618601T

Other languages

German (de)

English (en)

Other versions

DE69618601D1 (de

Inventor

Dennis L. Panicali

Jeffrey Schlom

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Therion Biologics Corp

US Department of Health and Human Services

Original Assignee

Therion Biologics Corp

US Department of Health and Human Services

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-10

Filing date

1996-06-26

Publication date

2002-08-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23988841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69618601(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-06-26 Application filed by Therion Biologics Corp, US Department of Health and Human Services filed Critical Therion Biologics Corp

2002-02-21 Publication of DE69618601D1 publication Critical patent/DE69618601D1/de

2002-08-08 Application granted granted Critical

2002-08-08 Publication of DE69618601T2 publication Critical patent/DE69618601T2/de

2016-06-27 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000028993 immune response Effects 0.000 title claims abstract description 20
238000004519 manufacturing process Methods 0.000 title claims description 5
108010072866 Prostate-Specific Antigen Proteins 0.000 claims abstract description 123
102000007066 Prostate-Specific Antigen Human genes 0.000 claims abstract description 121
239000013598 vector Substances 0.000 claims abstract description 41
238000000034 method Methods 0.000 claims abstract description 18
239000002671 adjuvant Substances 0.000 claims abstract description 12
238000003780 insertion Methods 0.000 claims abstract description 11
230000037431 insertion Effects 0.000 claims abstract description 11
239000000203 mixture Substances 0.000 claims abstract description 8
230000000737 periodic effect Effects 0.000 claims abstract description 6
238000009472 formulation Methods 0.000 claims abstract description 5
206010046865 Vaccinia virus infection Diseases 0.000 claims description 23
210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 23
208000007089 vaccinia Diseases 0.000 claims description 22
208000000666 Fowlpox Diseases 0.000 claims description 12
241000700629 Orthopoxvirus Species 0.000 claims description 5
231100000433 cytotoxic Toxicity 0.000 claims description 5
230000001472 cytotoxic effect Effects 0.000 claims description 5
241000700664 Capripoxvirus Species 0.000 claims description 4
241000700663 Avipoxvirus Species 0.000 claims description 3
YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 claims description 3
241000700568 Suipoxvirus Species 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
101150098638 RNASE1 gene Proteins 0.000 claims 1
102100039832 Ribonuclease pancreatic Human genes 0.000 claims 1
101150076131 rib-1 gene Proteins 0.000 claims 1
241000700605 Viruses Species 0.000 abstract description 38
230000014509 gene expression Effects 0.000 abstract description 13
239000013603 viral vector Substances 0.000 abstract description 7
230000024932 T cell mediated immunity Effects 0.000 abstract description 3
230000028996 humoral immune response Effects 0.000 abstract description 3
210000004027 cell Anatomy 0.000 description 63
108090000623 proteins and genes Proteins 0.000 description 50
241000282693 Cercopithecidae Species 0.000 description 32
108090000765 processed proteins & peptides Proteins 0.000 description 31
241001465754 Metazoa Species 0.000 description 30
230000003053 immunization Effects 0.000 description 28
238000002649 immunization Methods 0.000 description 27
108020004414 DNA Proteins 0.000 description 26
239000012634 fragment Substances 0.000 description 24
238000002255 vaccination Methods 0.000 description 23
241000700618 Vaccinia virus Species 0.000 description 21
239000000427 antigen Substances 0.000 description 21
108091007433 antigens Proteins 0.000 description 21
102000036639 antigens Human genes 0.000 description 21
241000282414 Homo sapiens Species 0.000 description 20
210000001744 T-lymphocyte Anatomy 0.000 description 19
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 19
241000282560 Macaca mulatta Species 0.000 description 16
102000004196 processed proteins & peptides Human genes 0.000 description 14
101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 13
101000592517 Homo sapiens Puromycin-sensitive aminopeptidase Proteins 0.000 description 13
206010060862 Prostate cancer Diseases 0.000 description 12
208000000236 Prostatic Neoplasms Diseases 0.000 description 12
239000002609 medium Substances 0.000 description 12
239000013612 plasmid Substances 0.000 description 12
210000002307 prostate Anatomy 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
206010028980 Neoplasm Diseases 0.000 description 9
235000018102 proteins Nutrition 0.000 description 9
230000004044 response Effects 0.000 description 9
108091028043 Nucleic acid sequence Proteins 0.000 description 8
230000005867 T cell response Effects 0.000 description 8
108020004440 Thymidine kinase Proteins 0.000 description 8
238000003556 assay Methods 0.000 description 8
230000001589 lymphoproliferative effect Effects 0.000 description 8
238000012360 testing method Methods 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
241000588724 Escherichia coli Species 0.000 description 7
239000000284 extract Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
108010058846 Ovalbumin Proteins 0.000 description 6
102000006601 Thymidine Kinase Human genes 0.000 description 6
125000003275 alpha amino acid group Chemical group 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
238000004820 blood count Methods 0.000 description 6
230000009089 cytolysis Effects 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
239000003550 marker Substances 0.000 description 6
229940092253 ovalbumin Drugs 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
108010002350 Interleukin-2 Proteins 0.000 description 5
102000000588 Interleukin-2 Human genes 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
230000006798 recombination Effects 0.000 description 5
238000005215 recombination Methods 0.000 description 5
229960005486 vaccine Drugs 0.000 description 5
238000002965 ELISA Methods 0.000 description 4
241000700647 Variola virus Species 0.000 description 4
108020005202 Viral DNA Proteins 0.000 description 4
230000003115 biocidal effect Effects 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000006801 homologous recombination Effects 0.000 description 4
238000002744 homologous recombination Methods 0.000 description 4
238000001802 infusion Methods 0.000 description 4
230000003902 lesion Effects 0.000 description 4
238000011471 prostatectomy Methods 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
230000008961 swelling Effects 0.000 description 4
238000001262 western blot Methods 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
108010062580 Concanavalin A Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241000700662 Fowlpox virus Species 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
108010071652 human kallikrein-related peptidase 3 Proteins 0.000 description 3
102000007579 human kallikrein-related peptidase 3 Human genes 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
206010061289 metastatic neoplasm Diseases 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
239000013641 positive control Substances 0.000 description 3
201000005825 prostate adenocarcinoma Diseases 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000012340 reverse transcriptase PCR Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000011282 treatment Methods 0.000 description 3
230000035899 viability Effects 0.000 description 3
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
108010082126 Alanine transaminase Proteins 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
241000450599 DNA viruses Species 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
101710103262 Glandular kallikrein Proteins 0.000 description 2
206010019842 Hepatomegaly Diseases 0.000 description 2
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
102000004889 Interleukin-6 Human genes 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
208000008771 Lymphadenopathy Diseases 0.000 description 2
241001467552 Mycobacterium bovis BCG Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
241000288906 Primates Species 0.000 description 2
241000700638 Raccoonpox virus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
206010041660 Splenomegaly Diseases 0.000 description 2
108010008038 Synthetic Vaccines Proteins 0.000 description 2
102000057032 Tissue Kallikreins Human genes 0.000 description 2
102100040247 Tumor necrosis factor Human genes 0.000 description 2
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
230000036755 cellular response Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000003255 drug test Methods 0.000 description 2
230000008029 eradication Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
230000008348 humoral response Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
101150066555 lacZ gene Proteins 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
150000007523 nucleic acids Chemical group 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
125000003835 nucleoside group Chemical group 0.000 description 2
235000020030 perry Nutrition 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
229940124551 recombinant vaccine Drugs 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
231100000027 toxicology Toxicity 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
LINMATFDVHBYOS-MBJXGIAVSA-N (2s,3r,4s,5r,6r)-2-[(5-bromo-1h-indol-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C=C12 LINMATFDVHBYOS-MBJXGIAVSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
108010029714 A2-binding peptide Proteins 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
102100037364 Craniofacial development protein 1 Human genes 0.000 description 1
102000004420 Creatine Kinase Human genes 0.000 description 1
108010042126 Creatine kinase Proteins 0.000 description 1
238000012270 DNA recombination Methods 0.000 description 1
206010011968 Decreased immune responsiveness Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000006586 Ectromelia Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010060708 Induration Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
102000000743 Interleukin-5 Human genes 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
241000700563 Leporipoxvirus Species 0.000 description 1
206010024503 Limb reduction defect Diseases 0.000 description 1
101001091390 Macaca mulatta Prostate-specific antigen Proteins 0.000 description 1
241000700627 Monkeypox virus Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
238000009004 PCR Kit Methods 0.000 description 1
241000282520 Papio Species 0.000 description 1
241001504519 Papio ursinus Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
241000700564 Rabbit fibroma virus Species 0.000 description 1
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
101000605527 Rattus norvegicus Kallikrein-1 Proteins 0.000 description 1
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
206010039509 Scab Diseases 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
206010053262 Skin swelling Diseases 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000700565 Swinepox virus Species 0.000 description 1
101150003725 TK gene Proteins 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
241001536558 Yaba monkey tumor virus Species 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000011467 adoptive cell therapy Methods 0.000 description 1
230000009824 affinity maturation Effects 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
125000000613 asparagine group Chemical class N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
230000008901 benefit Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
201000005332 contagious pustular dermatitis Diseases 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000001339 epidermal cell Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
244000052637 human pathogen Species 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
230000003908 liver function Effects 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
231100000682 maximum tolerated dose Toxicity 0.000 description 1
210000001806 memory b lymphocyte Anatomy 0.000 description 1
208000030247 mild fever Diseases 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
208000005871 monkeypox Diseases 0.000 description 1
UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
208000037920 primary disease Diseases 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
208000023958 prostate neoplasm Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000011472 radical prostatectomy Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
229940083538 smallpox vaccine Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000009121 systemic therapy Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

DE69618601T 1995-07-10 1996-06-26 Herstellung von einer immunantwort gegen prostat-spezifisches antigen (psa) Expired - Lifetime DE69618601T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/500,306 US6165460A (en)	1995-07-10	1995-07-10	Generation of immune responses to prostate-specific antigen (PSA)
PCT/US1996/010837 WO1997003203A2 (en)	1995-07-10	1996-06-26	Generation of immune responses to prostate-specific antigen (psa)

Publications (2)

Publication Number	Publication Date
DE69618601D1 DE69618601D1 (de)	2002-02-21
DE69618601T2 true DE69618601T2 (de)	2002-08-08

Family

ID=23988841

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE69637738T Expired - Lifetime DE69637738D1 (de)	1995-07-10	1996-06-26	Herstellung von einer Immunantwort gegen Prostat-spezifisches Antigen (SPA)
DE69618601T Expired - Lifetime DE69618601T2 (de)	1995-07-10	1996-06-26	Herstellung von einer immunantwort gegen prostat-spezifisches antigen (psa)

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE69637738T Expired - Lifetime DE69637738D1 (de)	1995-07-10	1996-06-26	Herstellung von einer Immunantwort gegen Prostat-spezifisches Antigen (SPA)

Country Status (11)

Country	Link
US (2)	US6165460A (es)
EP (2)	EP0840791B1 (es)
JP (3)	JP4633867B2 (es)
AT (2)	ATE212058T1 (es)
CA (1)	CA2226436C (es)
DE (2)	DE69637738D1 (es)
DK (2)	DK0840791T3 (es)
ES (2)	ES2320089T3 (es)
HK (1)	HK1042518B (es)
PT (2)	PT1162272E (es)
WO (1)	WO1997003203A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6699475B1 (en) *	1987-09-02	2004-03-02	Therion Biologics Corporation	Recombinant pox virus for immunization against tumor-associated antigens
US6165460A (en) *	1995-07-10	2000-12-26	Therion Biologics Corporation	Generation of immune responses to prostate-specific antigen (PSA)
US6946133B1 (en)	1996-03-20	2005-09-20	The United States Of America As Represented By The Department Of Health And Human Services	Prostate specific antigen oligo-epitope peptide
US20010036928A1 (en) *	1996-04-22	2001-11-01	Chamberlain Ronald S.	Heterologous boosting immunizations
EP0954593A1 (en)	1996-07-25	1999-11-10	Therion Biologics Corporation	Recombinant pox virus for immunization against tumor-associated antigens
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US7816087B2 (en)	2001-11-14	2010-10-19	The United States Of America As Represented By The Department Of Health And Human Services	Gene expressed in prostate cancer and methods of use
EP1512004B1 (en) *	2002-06-11	2006-03-15	MERCK PATENT GmbH	Method for mapping and eliminating t-cell epitopes
DE10230893A1 (de) *	2002-06-26	2004-01-15	Dr. Fischer Ag	Verfahren zur Eigenschaftsbestimmung und/oder Klassifikation von zirkulierenden Macrophagen und/oder peripheren blutmononuclearen Zellen sowie Analyseanordnung zur Durchführung des Verfahrens
US20040170646A1 (en) *	2002-12-13	2004-09-02	Aventis Pasteur, Inc.	Production of ALVAC on avian embryonic stem cells
WO2005005465A2 (en) *	2003-07-08	2005-01-20	Board Of Regents, University Of Texas System	Methods and compositions to enhance immune responses via recall antigens
US20070196346A1 (en) *	2003-08-21	2007-08-23	Brown Michael P	Poxvirus Vector Encoding Prostate Specific Antigens For Treatment Of Prostate Cancer
WO2006101503A2 (en) *	2004-06-15	2006-09-28	Centocor, Inc.	Method for screening agents against human prostate disease
JP2008546788A (ja) *	2005-06-21	2008-12-25	サイトパルスサイエンシズ、インコーポレイテッド	前立腺癌に対するワクチンに関する方法及び組成物
BRPI0708865A8 (pt)	2006-03-14	2019-01-22	Univ Oregon Health & Science	métodos para produzir uma resposta imune à tuberculose
CN105056226A (zh)	2006-12-27	2015-11-18	埃默里大学	用于治疗传染病和肿瘤的组合物和方法
AU2008221383B2 (en)	2007-02-28	2012-09-13	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Brachyury polypeptides and methods for use
KR101648087B1 (ko) *	2007-10-18	2016-08-17	버베리안 노딕 에이/에스	전립선 암 치료를 위한 ｍｖａ의 용도
WO2010050913A1 (en) *	2008-10-31	2010-05-06	The Brigham And Women's Hospital, Inc.	Vaccination with poxvirus vectors via mechanical epidermal disruption
US8691502B2 (en)	2008-10-31	2014-04-08	Tremrx, Inc.	T-cell vaccination with viral vectors via mechanical epidermal disruption
BRPI0921321A2 (pt)	2008-11-28	2018-10-16	Emory University	métodos para o tratamento de indwcções e tumores
US8664183B2 (en)	2009-02-27	2014-03-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	SPANX-B polypeptides and their use
WO2011063263A2 (en)	2009-11-20	2011-05-26	Oregon Health & Science University	Methods for producing an immune response to tuberculosis
AU2011285534B2 (en)	2010-08-06	2015-12-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Biomarkers for prostate cancer and methods for their detection
WO2014043518A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
WO2014097762A1 (ja) *	2012-12-20	2014-06-26	国立大学法人熊本大学	高病原性トリインフルエンザに対する抗体
WO2015175340A1 (en)	2014-05-13	2015-11-19	Bavarian Nordic, Inc.	Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
JP5917626B2 (ja) *	2014-07-28	2016-05-18	トレムアールエックス，インコーポレイテッド	機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
AU2016270428B2 (en)	2015-06-05	2020-11-26	Musc Foundation For Research Development	Endostatin fragments and variants for use in treating fibrosis
WO2017024000A1 (en)	2015-08-03	2017-02-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
US20190183870A1 (en)	2016-01-05	2019-06-20	The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services	Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en)	2016-02-02	2017-08-10	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
CA3133971A1 (en) *	2019-03-20	2020-09-24	Turnstone Biologics Inc.	Sequential heterologous boost oncolytic viral mmunotherapy
WO2023028451A2 (en)	2021-08-25	2023-03-02	Ibio, Inc.	Anti-cd-25 antibody

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5833975A (en) *	1989-03-08	1998-11-10	Virogenetics Corporation	Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
WO1989001973A2 (en) *	1987-09-02	1989-03-09	Applied Biotechnology, Inc.	Recombinant pox virus for immunization against tumor-associated antigens
US5093258A (en) *	1988-08-26	1992-03-03	Therion Biologics Corporation	Recombinant fowlpox virus and recombination vector
GB9105383D0 (en) *	1991-03-14	1991-05-01	Immunology Ltd	An immunotherapeutic for cervical cancer
ATE248924T1 (de) *	1991-05-06	2003-09-15	Us Gov Health & Human Serv	Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
ATE342356T1 (de) *	1992-11-05	2006-11-15	Sloan Kettering Inst Cancer	Prostata-spezifisches membranantigen
ATE303160T1 (de) *	1993-08-11	2005-09-15	Jenner Technologies	Impfstoff gegen prostatakrebs
FR2710536B1 (fr) *	1993-09-29	1995-12-22	Transgene Sa	Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
EP0652014A1 (en) *	1993-11-10	1995-05-10	National Institute Of Immunology	Treatment of prostatic hypertrophy
ZA941645B (en) *	1994-03-09	1995-01-13	South To South Co Operation In	Antibodies specifically reactive against human prostate specific antigen.
EP0725139A3 (en) *	1995-02-03	1997-11-26	Bayer Corporation	Recombinant prostate-specific antigen and its use as an immunoassay calibrator
US6165460A (en) *	1995-07-10	2000-12-26	Therion Biologics Corporation	Generation of immune responses to prostate-specific antigen (PSA)

1995
- 1995-07-10 US US08/500,306 patent/US6165460A/en not_active Expired - Lifetime
1996
- 1996-06-26 AT AT96923417T patent/ATE212058T1/de active
- 1996-06-26 DK DK96923417T patent/DK0840791T3/da active
- 1996-06-26 WO PCT/US1996/010837 patent/WO1997003203A2/en active IP Right Grant
- 1996-06-26 JP JP50583497A patent/JP4633867B2/ja not_active Expired - Lifetime
- 1996-06-26 DK DK01113517T patent/DK1162272T3/da active
- 1996-06-26 PT PT01113517T patent/PT1162272E/pt unknown
- 1996-06-26 EP EP96923417A patent/EP0840791B1/en not_active Expired - Lifetime
- 1996-06-26 ES ES01113517T patent/ES2320089T3/es not_active Expired - Lifetime
- 1996-06-26 ES ES96923417T patent/ES2172669T3/es not_active Expired - Lifetime
- 1996-06-26 AT AT01113517T patent/ATE413459T1/de active
- 1996-06-26 CA CA002226436A patent/CA2226436C/en not_active Expired - Fee Related
- 1996-06-26 DE DE69637738T patent/DE69637738D1/de not_active Expired - Lifetime
- 1996-06-26 PT PT96923417T patent/PT840791E/pt unknown
- 1996-06-26 DE DE69618601T patent/DE69618601T2/de not_active Expired - Lifetime
- 1996-06-26 EP EP01113517A patent/EP1162272B8/en not_active Expired - Lifetime
2000
- 2000-10-20 US US09/693,121 patent/US7598225B1/en not_active Expired - Lifetime
2002
- 2002-05-11 HK HK02103565.7A patent/HK1042518B/zh not_active IP Right Cessation
2006
- 2006-02-15 JP JP2006038681A patent/JP2006197938A/ja not_active Withdrawn
2008
- 2008-06-13 JP JP2008156031A patent/JP2008285492A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP1162272A2 (en)	2001-12-12
JP2006197938A (ja)	2006-08-03
JP2008285492A (ja)	2008-11-27
DE69618601D1 (de)	2002-02-21
WO1997003203A3 (en)	1997-04-17
EP1162272B1 (en)	2008-11-05
PT840791E (pt)	2002-06-28
ES2320089T3 (es)	2009-05-19
EP0840791B1 (en)	2002-01-16
EP1162272A3 (en)	2004-07-14
DK1162272T3 (da)	2009-03-09
DE69637738D1 (de)	2008-12-18
ATE212058T1 (de)	2002-02-15
HK1042518A1 (en)	2002-08-16
ATE413459T1 (de)	2008-11-15
US7598225B1 (en)	2009-10-06
WO1997003203A2 (en)	1997-01-30
EP0840791A2 (en)	1998-05-13
ES2172669T3 (es)	2002-10-01
JP4633867B2 (ja)	2011-02-16
US6165460A (en)	2000-12-26
JPH11509199A (ja)	1999-08-17
EP1162272B8 (en)	2010-03-10
PT1162272E (pt)	2009-02-16
HK1042518B (zh)	2009-04-17
CA2226436C (en)	2006-11-07
CA2226436A1 (en)	1997-01-30
DK0840791T3 (da)	2002-03-18

Publication	Publication Date	Title
DE69618601T2 (de)	2002-08-08	Herstellung von einer immunantwort gegen prostat-spezifisches antigen (psa)
DE69735995T2 (de)	2007-04-19	Oligoepitop-peptid des prostata-spezifischen antigens
JP4475683B2 (ja)	2010-06-09	腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス
Hodge et al.	1995	A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate
JP4364643B2 (ja)	2009-11-18	前立腺特異抗原のペプチドアゴニストおよびその使用
EP0811062B1 (en)	2009-07-15	Generation of human cytotoxic t-cells specific for carcinoma self-associated antigens and uses thereof
DE69936061T2 (de)	2008-01-17	Recombinanter vector, welcher mehrere kostimulatorische moleküle exprimiert und dessen verwenden
CA2388301C (en)	2011-01-04	Modified gp100 and uses thereof
CN112955177B (zh)	2024-10-25	真骨鱼恒定链癌症疫苗
US20070048860A1 (en)	2007-03-01	Carcinoembryonic antigen (CEA) peptides

Legal Events

Date	Code	Title	Description
2003-02-13	8364	No opposition during term of opposition